Loading…
Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review
•Systematic literature review of real-world 4CMenB vaccine effect outcomes was done.•Five identified studies showed large diversity, so no pooling of outcomes was done.•Vaccine estimates range for effectiveness was 59–94%, and for impact 31–75%.•Standardized tools to synthesize diverse real-world va...
Saved in:
| Published in: | Vaccine 2023-07, Vol.41 (30), p.4347-4358 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c440t-7a60ccfd1b41af0173480cfa24f8fbcad0ce46f5b14104c82900a4b7fc6f5eae3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c440t-7a60ccfd1b41af0173480cfa24f8fbcad0ce46f5b14104c82900a4b7fc6f5eae3 |
| container_end_page | 4358 |
| container_issue | 30 |
| container_start_page | 4347 |
| container_title | Vaccine |
| container_volume | 41 |
| creator | Cinconze, Elisa Rosillon, Dominique Rappuoli, Rino Vadivelu, Kumaran Bekkat-Berkani, Rafik Abbing-Karahagopian, Victoria |
| description | •Systematic literature review of real-world 4CMenB vaccine effect outcomes was done.•Five identified studies showed large diversity, so no pooling of outcomes was done.•Vaccine estimates range for effectiveness was 59–94%, and for impact 31–75%.•Standardized tools to synthesize diverse real-world vaccine estimates are needed.
Real-world studies on vaccine effects are diverse in terms of objectives, study setting and design, data type and scope, and analysis methods. In this review, we describe and discuss four-component meningococcal serogroup B vaccine (4CMenB vaccine, Bexsero) real-world studies with the aim of synthesizing their findings with application of standard methods.
We performed a systematic literature review of all real-world studies on 4CMenB vaccine effects on meningococcal serogroup B disease, with no restriction for population age, vaccination schedule and/or type of vaccine effect evaluated (vaccine effectiveness [VE] and vaccine impact [VI] outcomes) published since its licensure in 2013 (from January 2014 until July 2021) in PubMed, Cochrane and the grey literature. We then aimed to synthesize the findings of the identified studies through application of standard synthesis methods.
According to reported criteria we retrieved five studies presenting estimates on 4CMenB vaccine effectiveness and impact. These studies showed great diversity in population, vaccination schedule and analysis methods mainly due to diversity in vaccine strategies and recommendations in the study settings. Directed by this diversity, no quantitative pooling methods to synthesize findings could be applied; instead we descriptively assessed study methods. We report VE estimates ranging from 59% to 94% and VI estimates ranging from 31% to 75%, representing diverse age groups, vaccination schedules and analysis methods.
Both vaccine outcomes showed real-life effectiveness of 4CMenB vaccine despite differences in study methodologies and vaccination strategies. Based on appraisal of study methods, we highlighted the need for an adapted tool which facilitates synthesis of heterogenic real-world vaccine studies when quantitative pooling methods are not applicable. |
| doi_str_mv | 10.1016/j.vaccine.2023.05.025 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2827252689</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X23005522</els_id><sourcerecordid>2827252689</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-7a60ccfd1b41af0173480cfa24f8fbcad0ce46f5b14104c82900a4b7fc6f5eae3</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxSMEokvhI4AsceklYezYSZYLalf8k4q4gMTNcpzx1qvEXjzJVv1EfE1c7bYHLpwsjX9v5um9onjNoeLAm3e76mCs9QErAaKuQFUg1JNixbu2LoXi3dNiBaKRpeTw66x4QbQDAFXz9fPirG5rwbu1WhV_NjdmHDFskZgPjO7CfIPkiUXHEpqxvI1pHNjpFkPn0M75N7AJgw_baKO1ZmSEKW5TXPbsig2e0BAyFxOTm28Yrh71-0hzOXqLgZb0sM4fMCARo3kZPNJ7dpl90IyTmb3NLg4eb18Wz5wZCV-d3vPi56ePPzZfyuvvn79uLq9LKyXMZWsasNYNvJfcOOBtLTuwzgjpOtdbM4BF2TjV8xyLtJ1YAxjZt87mIRqsz4uL4959ir8XpFlPniyOowkYF9KiE61QounWGX37D7qLSwrZXaZqaBpQgmdKHSmbIlFCp_fJTybdaQ76vkm906d09H2TGpTOTWbdm9P2pZ9weFQ9VJeBD0cAcxw5oqTJegwWB59yqHqI_j8n_gL-RrXW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2830660521</pqid></control><display><type>article</type><title>Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review</title><source>ScienceDirect Freedom Collection</source><creator>Cinconze, Elisa ; Rosillon, Dominique ; Rappuoli, Rino ; Vadivelu, Kumaran ; Bekkat-Berkani, Rafik ; Abbing-Karahagopian, Victoria</creator><creatorcontrib>Cinconze, Elisa ; Rosillon, Dominique ; Rappuoli, Rino ; Vadivelu, Kumaran ; Bekkat-Berkani, Rafik ; Abbing-Karahagopian, Victoria</creatorcontrib><description>•Systematic literature review of real-world 4CMenB vaccine effect outcomes was done.•Five identified studies showed large diversity, so no pooling of outcomes was done.•Vaccine estimates range for effectiveness was 59–94%, and for impact 31–75%.•Standardized tools to synthesize diverse real-world vaccine estimates are needed.
Real-world studies on vaccine effects are diverse in terms of objectives, study setting and design, data type and scope, and analysis methods. In this review, we describe and discuss four-component meningococcal serogroup B vaccine (4CMenB vaccine, Bexsero) real-world studies with the aim of synthesizing their findings with application of standard methods.
We performed a systematic literature review of all real-world studies on 4CMenB vaccine effects on meningococcal serogroup B disease, with no restriction for population age, vaccination schedule and/or type of vaccine effect evaluated (vaccine effectiveness [VE] and vaccine impact [VI] outcomes) published since its licensure in 2013 (from January 2014 until July 2021) in PubMed, Cochrane and the grey literature. We then aimed to synthesize the findings of the identified studies through application of standard synthesis methods.
According to reported criteria we retrieved five studies presenting estimates on 4CMenB vaccine effectiveness and impact. These studies showed great diversity in population, vaccination schedule and analysis methods mainly due to diversity in vaccine strategies and recommendations in the study settings. Directed by this diversity, no quantitative pooling methods to synthesize findings could be applied; instead we descriptively assessed study methods. We report VE estimates ranging from 59% to 94% and VI estimates ranging from 31% to 75%, representing diverse age groups, vaccination schedules and analysis methods.
Both vaccine outcomes showed real-life effectiveness of 4CMenB vaccine despite differences in study methodologies and vaccination strategies. Based on appraisal of study methods, we highlighted the need for an adapted tool which facilitates synthesis of heterogenic real-world vaccine studies when quantitative pooling methods are not applicable.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2023.05.025</identifier><identifier>PMID: 37321895</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Effectiveness ; Effectiveness studies ; Estimates ; Grey literature ; Immunization ; Licenses ; Literature reviews ; Meta-analysis ; Observational studies ; Real-world evidence ; Schedules ; Statistical analysis ; Synthesis ; Synthesis of effectiveness/impact ; Systematic review ; Vaccine efficacy ; Vaccines</subject><ispartof>Vaccine, 2023-07, Vol.41 (30), p.4347-4358</ispartof><rights>2023 GSK</rights><rights>Copyright © 2023 GSK. Published by Elsevier Ltd.. All rights reserved.</rights><rights>2023. GSK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-7a60ccfd1b41af0173480cfa24f8fbcad0ce46f5b14104c82900a4b7fc6f5eae3</citedby><cites>FETCH-LOGICAL-c440t-7a60ccfd1b41af0173480cfa24f8fbcad0ce46f5b14104c82900a4b7fc6f5eae3</cites><orcidid>0000-0003-1987-363X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37321895$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cinconze, Elisa</creatorcontrib><creatorcontrib>Rosillon, Dominique</creatorcontrib><creatorcontrib>Rappuoli, Rino</creatorcontrib><creatorcontrib>Vadivelu, Kumaran</creatorcontrib><creatorcontrib>Bekkat-Berkani, Rafik</creatorcontrib><creatorcontrib>Abbing-Karahagopian, Victoria</creatorcontrib><title>Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•Systematic literature review of real-world 4CMenB vaccine effect outcomes was done.•Five identified studies showed large diversity, so no pooling of outcomes was done.•Vaccine estimates range for effectiveness was 59–94%, and for impact 31–75%.•Standardized tools to synthesize diverse real-world vaccine estimates are needed.
Real-world studies on vaccine effects are diverse in terms of objectives, study setting and design, data type and scope, and analysis methods. In this review, we describe and discuss four-component meningococcal serogroup B vaccine (4CMenB vaccine, Bexsero) real-world studies with the aim of synthesizing their findings with application of standard methods.
We performed a systematic literature review of all real-world studies on 4CMenB vaccine effects on meningococcal serogroup B disease, with no restriction for population age, vaccination schedule and/or type of vaccine effect evaluated (vaccine effectiveness [VE] and vaccine impact [VI] outcomes) published since its licensure in 2013 (from January 2014 until July 2021) in PubMed, Cochrane and the grey literature. We then aimed to synthesize the findings of the identified studies through application of standard synthesis methods.
According to reported criteria we retrieved five studies presenting estimates on 4CMenB vaccine effectiveness and impact. These studies showed great diversity in population, vaccination schedule and analysis methods mainly due to diversity in vaccine strategies and recommendations in the study settings. Directed by this diversity, no quantitative pooling methods to synthesize findings could be applied; instead we descriptively assessed study methods. We report VE estimates ranging from 59% to 94% and VI estimates ranging from 31% to 75%, representing diverse age groups, vaccination schedules and analysis methods.
Both vaccine outcomes showed real-life effectiveness of 4CMenB vaccine despite differences in study methodologies and vaccination strategies. Based on appraisal of study methods, we highlighted the need for an adapted tool which facilitates synthesis of heterogenic real-world vaccine studies when quantitative pooling methods are not applicable.</description><subject>Age</subject><subject>Effectiveness</subject><subject>Effectiveness studies</subject><subject>Estimates</subject><subject>Grey literature</subject><subject>Immunization</subject><subject>Licenses</subject><subject>Literature reviews</subject><subject>Meta-analysis</subject><subject>Observational studies</subject><subject>Real-world evidence</subject><subject>Schedules</subject><subject>Statistical analysis</subject><subject>Synthesis</subject><subject>Synthesis of effectiveness/impact</subject><subject>Systematic review</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkU9v1DAQxSMEokvhI4AsceklYezYSZYLalf8k4q4gMTNcpzx1qvEXjzJVv1EfE1c7bYHLpwsjX9v5um9onjNoeLAm3e76mCs9QErAaKuQFUg1JNixbu2LoXi3dNiBaKRpeTw66x4QbQDAFXz9fPirG5rwbu1WhV_NjdmHDFskZgPjO7CfIPkiUXHEpqxvI1pHNjpFkPn0M75N7AJgw_baKO1ZmSEKW5TXPbsig2e0BAyFxOTm28Yrh71-0hzOXqLgZb0sM4fMCARo3kZPNJ7dpl90IyTmb3NLg4eb18Wz5wZCV-d3vPi56ePPzZfyuvvn79uLq9LKyXMZWsasNYNvJfcOOBtLTuwzgjpOtdbM4BF2TjV8xyLtJ1YAxjZt87mIRqsz4uL4959ir8XpFlPniyOowkYF9KiE61QounWGX37D7qLSwrZXaZqaBpQgmdKHSmbIlFCp_fJTybdaQ76vkm906d09H2TGpTOTWbdm9P2pZ9weFQ9VJeBD0cAcxw5oqTJegwWB59yqHqI_j8n_gL-RrXW</recordid><startdate>20230705</startdate><enddate>20230705</enddate><creator>Cinconze, Elisa</creator><creator>Rosillon, Dominique</creator><creator>Rappuoli, Rino</creator><creator>Vadivelu, Kumaran</creator><creator>Bekkat-Berkani, Rafik</creator><creator>Abbing-Karahagopian, Victoria</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1987-363X</orcidid></search><sort><creationdate>20230705</creationdate><title>Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review</title><author>Cinconze, Elisa ; Rosillon, Dominique ; Rappuoli, Rino ; Vadivelu, Kumaran ; Bekkat-Berkani, Rafik ; Abbing-Karahagopian, Victoria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-7a60ccfd1b41af0173480cfa24f8fbcad0ce46f5b14104c82900a4b7fc6f5eae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Age</topic><topic>Effectiveness</topic><topic>Effectiveness studies</topic><topic>Estimates</topic><topic>Grey literature</topic><topic>Immunization</topic><topic>Licenses</topic><topic>Literature reviews</topic><topic>Meta-analysis</topic><topic>Observational studies</topic><topic>Real-world evidence</topic><topic>Schedules</topic><topic>Statistical analysis</topic><topic>Synthesis</topic><topic>Synthesis of effectiveness/impact</topic><topic>Systematic review</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cinconze, Elisa</creatorcontrib><creatorcontrib>Rosillon, Dominique</creatorcontrib><creatorcontrib>Rappuoli, Rino</creatorcontrib><creatorcontrib>Vadivelu, Kumaran</creatorcontrib><creatorcontrib>Bekkat-Berkani, Rafik</creatorcontrib><creatorcontrib>Abbing-Karahagopian, Victoria</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cinconze, Elisa</au><au>Rosillon, Dominique</au><au>Rappuoli, Rino</au><au>Vadivelu, Kumaran</au><au>Bekkat-Berkani, Rafik</au><au>Abbing-Karahagopian, Victoria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2023-07-05</date><risdate>2023</risdate><volume>41</volume><issue>30</issue><spage>4347</spage><epage>4358</epage><pages>4347-4358</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-3</notes><notes>content type line 23</notes><notes>ObjectType-Review-1</notes><notes>ObjectType-Undefined-4</notes><abstract>•Systematic literature review of real-world 4CMenB vaccine effect outcomes was done.•Five identified studies showed large diversity, so no pooling of outcomes was done.•Vaccine estimates range for effectiveness was 59–94%, and for impact 31–75%.•Standardized tools to synthesize diverse real-world vaccine estimates are needed.
Real-world studies on vaccine effects are diverse in terms of objectives, study setting and design, data type and scope, and analysis methods. In this review, we describe and discuss four-component meningococcal serogroup B vaccine (4CMenB vaccine, Bexsero) real-world studies with the aim of synthesizing their findings with application of standard methods.
We performed a systematic literature review of all real-world studies on 4CMenB vaccine effects on meningococcal serogroup B disease, with no restriction for population age, vaccination schedule and/or type of vaccine effect evaluated (vaccine effectiveness [VE] and vaccine impact [VI] outcomes) published since its licensure in 2013 (from January 2014 until July 2021) in PubMed, Cochrane and the grey literature. We then aimed to synthesize the findings of the identified studies through application of standard synthesis methods.
According to reported criteria we retrieved five studies presenting estimates on 4CMenB vaccine effectiveness and impact. These studies showed great diversity in population, vaccination schedule and analysis methods mainly due to diversity in vaccine strategies and recommendations in the study settings. Directed by this diversity, no quantitative pooling methods to synthesize findings could be applied; instead we descriptively assessed study methods. We report VE estimates ranging from 59% to 94% and VI estimates ranging from 31% to 75%, representing diverse age groups, vaccination schedules and analysis methods.
Both vaccine outcomes showed real-life effectiveness of 4CMenB vaccine despite differences in study methodologies and vaccination strategies. Based on appraisal of study methods, we highlighted the need for an adapted tool which facilitates synthesis of heterogenic real-world vaccine studies when quantitative pooling methods are not applicable.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>37321895</pmid><doi>10.1016/j.vaccine.2023.05.025</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-1987-363X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2023-07, Vol.41 (30), p.4347-4358 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2827252689 |
| source | ScienceDirect Freedom Collection |
| subjects | Age Effectiveness Effectiveness studies Estimates Grey literature Immunization Licenses Literature reviews Meta-analysis Observational studies Real-world evidence Schedules Statistical analysis Synthesis Synthesis of effectiveness/impact Systematic review Vaccine efficacy Vaccines |
| title | Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T03%3A12%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Challenges%20in%20synthesis%20of%20real-world%20vaccine%20effects%20on%20meningococcal%20serogroup%20B%20disease%20for%204CMenB%20vaccine%20post-licensure%20effectiveness%20studies:%20A%20systematic%20review&rft.jtitle=Vaccine&rft.au=Cinconze,%20Elisa&rft.date=2023-07-05&rft.volume=41&rft.issue=30&rft.spage=4347&rft.epage=4358&rft.pages=4347-4358&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2023.05.025&rft_dat=%3Cproquest_cross%3E2827252689%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c440t-7a60ccfd1b41af0173480cfa24f8fbcad0ce46f5b14104c82900a4b7fc6f5eae3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2830660521&rft_id=info:pmid/37321895&rfr_iscdi=true |